Estimates Revisions Spero Therapeutics, Inc.
Stocks
SPRO
US84833T1034
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
00:00:00 28/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 1.210 USD | -0.82% |
|
-1.63% | -48.07% |
| 08-13 | Spero Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 | |
| 08-13 | Spero Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Earnings Per Share (EPS)
- Stock Market
- Stocks
- SPRO Stock
- Consensus Spero Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
